Skip to main content

Chickenpox

9
Pipeline Programs
7
Companies
10
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
5
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1083%
Small Molecule
217%
+ 4 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Medica Corp
Medica CorpMA - Bedford
2 programs
2
Live Attenuated Varicella VaccinePhase 4Vaccine1 trial
Live Attenuated Varicella VaccinePhase 4Vaccine1 trial
Active Trials
NCT01982409Unknown350Est. Dec 2018
NCT01817270Completed368Est. Aug 2013
Vabiotech
VabiotechVietnam - Hanoi
1 program
1
Skyvaricella InjectionPhase 41 trial
Active Trials
NCT04384016Completed201Est. Apr 2022
ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
1
4
Candidate varicella vaccinePhase 3Vaccine
Investigational varicella vaccinePhase 3Vaccine
Investigational varicella vaccinePhase 3Vaccine
Investigational varicella vaccine_Lot 1Phase 3
Investigational varicella vaccine low potencyPhase 2Vaccine
Sandoz
SandozAustria - Kundl
1 program
1
famciclovirPhase 3Small Molecule1 trial
Active Trials
NCT00098046Completed76Est. Jul 2007
GSK
GSKLONDON, United Kingdom
5 programs
Investigational varicella vaccine low potencyPHASE_2Vaccine1 trial
Candidate varicella vaccinePHASE_3Vaccine1 trial
Investigational varicella vaccinePHASE_3Vaccine1 trial
Investigational varicella vaccinePHASE_3Vaccine1 trial
Investigational varicella vaccine_Lot 1PHASE_31 trial
Active Trials
NCT05084508Completed800Est. Jun 2024
NCT06855160Recruiting900Est. Feb 2027
NCT06806137Recruiting600Est. May 2027
+2 more trials
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Immune Response to Varicella-Zoster Vaccination and InfectionN/A1 trial
Active Trials
NCT00921999Completed19Est. Jan 2015
Novartis
NovartisBASEL, Switzerland
1 program
famciclovirPHASE_3Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
VabiotechSkyvaricella Injection
Medica CorpLive Attenuated Varicella Vaccine
Medica CorpLive Attenuated Varicella Vaccine
GSKInvestigational varicella vaccine
GSKCandidate varicella vaccine
GSKInvestigational varicella vaccine_Lot 1
GSKInvestigational varicella vaccine
Sandozfamciclovir
GSKInvestigational varicella vaccine low potency
Allergy TherapeuticsImmune Response to Varicella-Zoster Vaccination and Infection

Clinical Trials (10)

Total enrollment: 5,904 patients across 10 trials

NCT04384016VabiotechSkyvaricella Injection

Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old

Start: Apr 2021Est. completion: Apr 2022201 patients
Phase 4Completed
NCT01982409Medica CorpLive Attenuated Varicella Vaccine

Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children

Start: Jun 2013Est. completion: Dec 2018350 patients
Phase 4Unknown
NCT01817270Medica CorpLive Attenuated Varicella Vaccine

Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine

Start: Mar 2013Est. completion: Aug 2013368 patients
Phase 4Completed
NCT06806137GSKInvestigational varicella vaccine

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Start: May 2025Est. completion: May 2027600 patients
Phase 3Recruiting
NCT06855160GSKCandidate varicella vaccine

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Start: Apr 2025Est. completion: Feb 2027900 patients
Phase 3Recruiting
NCT06740630GSKInvestigational varicella vaccine_Lot 1

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Start: Jan 2025Est. completion: May 20271,840 patients
Phase 3Recruiting
NCT06693895GSKInvestigational varicella vaccine

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Start: Nov 2024Est. completion: Nov 2026750 patients
Phase 3Recruiting
NCT00098046Sandozfamciclovir

Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection

Start: Jul 2005Est. completion: Jul 200776 patients
Phase 3Completed
NCT05084508GSKInvestigational varicella vaccine low potency

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Start: Feb 2022Est. completion: Jun 2024800 patients
Phase 2Completed
NCT00921999Allergy TherapeuticsImmune Response to Varicella-Zoster Vaccination and Infection

Immune Response to Varicella-Zoster Vaccination and Infection

Start: Jun 2009Est. completion: Jan 201519 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 5,904 patients
Vaccine is the dominant modality (83% of programs)
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.